DOCSLIB.ORG

Reflection Paper on the Use of Aminopenicillins and Their Beta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reflection Paper on the Use of Aminopenicillins and Their Beta 1 13 September 2018 2 EMA/CVMP/AWP/842786/2015 3 Committee for Medicinal Products for Veterinary Use (CVMP) 4 Reflection paper on the use of aminopenicillins and their 5 beta-lactamase inhibitor combinations in animals in the 6 European Union: development of resistance and impact 7 on human and animal health 8 Draft Draft agreed by Antimicrobials Working Party (AWP) 9 July 2018 Adopted by CVMP for release for consultation 13 September 2018 Start of public consultation 21 September 2018 End of consultation (deadline for comments) 21 December 2018 9 Comments should be provided using this template. The completed comments form should be sent to [email protected] 10 Keywords aminopenicillins, antimicrobial resistance 11 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 12 13 Table of contents 14 Executive summary ..................................................................................... 4 15 CVMP Recommendations for action ............................................................. 6 16 1. Background ............................................................................................. 7 17 2. General drug characteristics .................................................................... 8 18 2.1. Structure and mechanism of action ....................................................................... 8 19 2.2. Antimicrobial spectrum ....................................................................................... 8 20 2.3. Pharmacodynamics ............................................................................................. 9 21 2.4. Pharmacokinetics ............................................................................................. 10 22 3. Resistance mechanisms and susceptibility testing ................................ 12 23 3.1. Resistance mechanisms .................................................................................... 12 24 3.1.1. Enzymatic degradation of beta-lactams by beta-lactamases ................................. 12 25 3.1.2. Modification of the target site .......................................................................... 17 26 3.1.3. Other resistance mechanisms .......................................................................... 17 27 3.2. Susceptibility testing ........................................................................................ 17 28 4. Sales and use of aminopenicillins and their inhibitor combinations in 29 veterinary medicine ................................................................................... 19 30 4.1. Sales .............................................................................................................. 19 31 4.2. Use and indications in food-producing animals ...................................................... 19 32 4.3. Use and indications in horses ............................................................................. 20 33 4.4. Use and indications in companion animals ........................................................... 21 34 5. The use of aminopenicillins and their inhibitor combinations in human 35 medicine .................................................................................................... 25 36 5.1. Indications in human medicine ........................................................................... 25 37 5.2. Consumption of aminopenicillins in humans in the EU ............................................ 26 38 6. Occurrence of resistance ....................................................................... 29 39 6.1. Resistance in bacteria of animal origin covered by EU surveillance ........................... 30 40 6.2. Resistance in animal target pathogens ................................................................ 31 41 6.3. Resistance in human pathogens ......................................................................... 34 42 7. Possible links between the use of aminopenicillins and their inhibitor 43 combinations in animals and resistance in bacteria of animal origin ......... 36 44 8. Impact of resistance on animal and human health ................................ 37 45 8.1. Animal health .................................................................................................. 37 46 8.2. Human health .................................................................................................. 38 47 9. Transmission of resistance or resistance determinants between animals 48 and humans ............................................................................................... 39 49 9.1. Transmission of resistant bacteria ....................................................................... 39 50 9.2. Transmission of resistance determinants ............................................................. 41 Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health EMA/CVMP/AWP/842786/2015 Page 2/65 51 10. Discussion ........................................................................................... 44 52 11. Conclusions ......................................................................................... 46 53 12. References .......................................................................................... 53 54 Appendix ................................................................................................... 65 55 56 Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health EMA/CVMP/AWP/842786/2015 Page 3/65 57 Executive summary 58 The objective of this document is to review available information on the use of aminopenicillins and 59 their beta-lactamase inhibitor combinations in veterinary medicine in the EU, their effect on the 60 emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and 61 animal health. The document provides information for the risk profiling, as recommended by the 62 Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA, to assist with placing these substances 63 within the AMEG’s categorisation (EMA/AMEG, 2014). The focus of this paper is on veterinary 64 aminopenicillins authorised in the EU, which are ampicillin (ATC J01CA01), amoxicillin (ATC J01CA04), 65 and their beta-lactamase inhibitor combination amoxicillin-clavulanic acid (J01CR02). 66 The WHO classifies penicillins (natural, aminopenicillins and antipseudomonal) as critically important 67 antimicrobials (CIA) for humans. According to the WHO, the CIA status is justified due to limited 68 therapy options for listeriosis and infections caused by Enterococcus spp., and the likelihood of 69 transmission of resistant Enterococcus spp. and Enterobacteriaceae, including both Salmonella spp. 70 and Escherichia coli, from non-human sources to humans. 71 Although aminopenicillins are seldom among the sole treatment options, with the exception of for 72 Listeria and enterococci, they are often used as first line antimicrobials for many infections in animals 73 and humans. In animals aminopenicillins are used for infections caused by species belonging to 74 Pasteurellaceae, Streptococcus spp., Staphylococcus spp., Erysipelothrix rhusiopathiae, Listeria 75 monocytogenes, Clostridium spp. and other anaerobic species, Bordetella bronchiseptica and species 76 belonging to the Enterobacteriaceae. Aminopenicillins and their inhibitor combinations are very 77 valuable drugs for treating respiratory infections in humans caused by Streptococcus pneumoniae, 78 Haemophilus influenzae, and Branhamella catarrhalis. Due to the abundant presence of beta- 79 lactamases in E. coli and in many other Enterobacteriaceae, aminopenicillins are combined with beta- 80 lactamase inhibitors for the treatment of infections caused by these bacteria. Inhibitor combinations 81 can also be useful in certain infections caused by ESBL-producing E.coli provided that an isolate is 82 susceptible to the combination in vitro. The combination is ineffective against AmpC-mediated 83 resistance. 84 Ampicillin, amoxicillin, and to a lesser extent amoxicillin-clavulanic acid combinations have been widely 85 used for decades for the treatment of infections in several animal species in European countries. 86 Measured in mg/PCU (population correction unit), penicillins were the second most used antimicrobial 87 class in food-producing animals in the EU in 2015 and accounted for 25% of the total sales. 88 Aminopenicillins (amoxicillin) made up the major proportion (88%) of the total penicillin use, while 89 their inhibitor combinations formed a very limited fraction of the total penicillin use. There are 90 substantial differences between the uses of different beta-lactam drug classes in animals in Nordic 91 countries, where benzyl penicillin and its pro-drugs dominates, vs. in other European countries, where 92 aminopenicillins are the prevailing beta-lactams used. This may be due to differences in treatment 93 guidelines, availability of authorised products, production systems (including dominant animal species), 94 herd sizes, disease occurrences, and production
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith Et Al
    USOO9662400B2 (12) United States Patent (10) Patent No.: US 9,662.400 B2 Smith et al. (45) Date of Patent: *May 30, 2017 (54) METHODS FOR PRODUCING A (2013.01); C08B 37/003 (2013.01); C08L 5/08 BODEGRADABLE CHITOSAN (2013.01); A6 IK 38/00 (2013.01); A61 L COMPOSITION AND USES THEREOF 2300/404 (2013.01) (58) Field of Classification Search (71) Applicant: University of Memphis Research CPC ...... A61K 47/36; A61K 31/00; A61K 9/7007; Foundation, Memphis, TN (US) A61K 9/0024; A61 L 15/28: A61L 27/20; A61L 27/58: A61L 31/042; C08B 37/003 (72) Inventors: James Keaton Smith, Memphis, TN USPC ................................ 514/23, 40, 777; 536/20 (US); Ashley C. Parker, Memphis, TN See application file for complete search history. (US); Jessica A. Jennings, Memphis, (56) References Cited TN (US); Benjamin T. Reves, Memphis, TN (US); Warren O. U.S. PATENT DOCUMENTS Haggard, Bartlett, TN (US) 4,895,724. A * 1/1990 Cardinal .............. A61K9/0024 424,278.1 (73) Assignee: The University of Memphis Research 5,541,233 A 7/1996 Roenigk Foundation, Memphis, TN (US) 5,958,443 A 9/1999 Viegas et al. 6,699,287 B2 3/2004 Son et al. (*) Notice: Subject to any disclaimer, the term of this 6,989,157 B2 1/2006 Gillis et al. patent is extended or adjusted under 35 7,371.403 B2 5/2008 McCarthy et al. 2003, OO15825 A1 1/2003 Sugie et al. U.S.C. 154(b) by 0 days. 2003/0206958 A1 11/2003 Cattaneo et al.
    [Show full text]
  • Derivatives of Clavulanic Acid, Process for Their Preparation And
    Europaisches Patentamt © ê European Patent Office © Publication number: 0 003 254 Office européen des brevets Bl © EUROPEAN PATENT SPECIFICATION (45) Date of publication of patent spécification: 28.03.84 © Int. ci.3: C 07 D 498/04, A 61 K 31/42, @ Application number: 78300762.8 A 61 K 31/43, @ Date offiling: 07.12.78 A 61 K 31/545 //(C07D498/04, 263/00, 205/00), (A6 1 K3 1 /43, 3 1/42), (A61K3 1/545, 31/42) (54) Derivatives of clavulanic acid, process for their préparation and compositions containing them. (§) Priority: 26.01 .78 GB 312978 @ Proprietor: BEECHAM GROUP PLC Beecham House Great West Road Brentford Middlesex (GB) (43) Date of publication of application: 08.08.79 Bulletin 79/1 6 @ Inventor: Gasson, Brian Charles 9, Clarence Walk (45) Publication of the grant of the patent: Redhill Surrey (GB) 28.03.84 Bulletin 84/13 © Représentative: Hesketh, Alan, Dr. et al, (84) Designated Contracting States: European Patent Attorney Beecham BE CH DEFRGBITNL Pharmaceuticals Great Burgh Yew Tree Bottom Road Epsom, Surrey, KT18 5XQ (GB) (56) Références cited: BE - A - 847 046 The file contains technical information submitted after the application was filed and not included in this spécification Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • Simultaneous Determination of Amoxicillin and Clavulanic Acid in Pharmaceutical Preparations by Capillary Zone Electrophoresis
    Brazilian Journal of Pharmaceutical Sciences vol. 52, n. 2, apr./jun., 2016 Article http://dx.doi.org/10.1590/S1984-82502016000200006 Simultaneous determination of amoxicillin and clavulanic acid in pharmaceutical preparations by capillary zone electrophoresis Gabriel Hancu1,*, Anamaria Neacşu1, Lajos Attila Papp1, Adriana Ciurba2 1Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy, TîrguMureş, Romania, 2Department of PharmaceuticalTechnology, Faculty of Pharmacy, University of Medicine and Pharmacy, Tîrgu Mureş, Romania Clavulanic acid enhances the antibacterial spectrum of amoxicillin by rendering most β-lactamase producing isolates susceptible to the drug. A fast, simple and efficient capillary electrophoresis method was developed for the simultaneous determination of amoxicillin and clavulanic acid from complex mixtures. Using a 25 mM sodium tetraborate as background electrolyte at a pH of 9.30, + 25 kV applied voltage, 25 °C system temperature, UV determination at 230 nm; we succeeded in simultaneous separation of amoxicillin and clavulanic acid in approximately 2 minutes. The analytical performance of the method was evaluated in terms of reproducibility, precision, accuracy, and linearity. The optimized analytical method was applied for the determination of the two analytes from combined commercial pharmaceutical preparations. This CE method is fast, inexpensive, efficient, and environmentally friendly when compared with the more frequently used high performance liquid chromatography methods described in the literature. Uniterms: Amoxicillin/determination. Clavulanic acid/determination. Capillary electrophoresis/ quantitative analysis. Antibacterials/quantitative analysis. O ácido clavulânico acentua o espectro antibacteriano de amoxicilina, tornando a maioria dos isolados produtores de β-lactamase sensíveis ao fármaco. Desenvolveu-se um método rápido, simples e eficiente de electroforese capilar (EC) para a determinação simultânea de amoxicilina e de ácido clavulânico a partir de misturas complexas.
    [Show full text]
  • Mechanisms of Resistance to P-Lactam Antibiotics Amongst 1993
    J. Med. Microbiol. - Vol. 43 (1999, 30G309 0 1995 The Pathological Society of Great Britain and Ireland ANTI MICROBIAL AGENTS Mechanisms of resistance to p-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993 H. Y. CHEN, ME1 YUAN and D. M. LIVERMORE Department of Medical Microbiology, The London Hospital Medical College, Turner Street, London El 2AD Summary. Antimicrobial resistance among 199 1 Pseudomonas aeruginosa isolates collected at 24 UK hospitals during late 1993 was surveyed. Three-hundred and seventy-two of the isolates were resistant, or had reduced susceptibility, to some or all of azlocillin, carbenicillin, ceftazidime, imipenem and meropenem, and the mechanisms underlying their behaviour were examined. Only 13 isolates produced secondary p-lactamases : six possessed PSE- 1 or PSE-4 enzymes and seven had novel OXA enzyme types. Those with PSE types were highly resistant to azlocillin and carbenicillin whereas those with OXA enzymes were less resistant to these penicillins. Chromosomal p-lactamase derepression was demonstrated in 54 isolates, most of which were resistant to ceftazidime and azlocillin although susceptible to carbenicillin and carbapenems. p-Lactamase-independent “ intrinsic” resistance occurred in 277 isolates and is believed to reflect some combination of impermeability and efflux. Two forms were seen : the classical type, present in 195 isolates, gave carbenicillin resistance (MIC > 128 mg/L) and reduced susceptibility to ciprofloxacin and to all p-lactam agents except imipenem; a novel variant, seen in 82 isolates, affected only azlocillin, ceftazidime and, to a small extent, meropenem. Resistance to imipenem was largely dissociated from that to other p-lactam agents, and probably reflected loss of D2 porin, whereas resistance to meropenem was mostly associated with intrinsic resistance to penicillins and cephalosporins.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Antibacterial Drug Usage Analysis
    Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Office of Surveillance and Epidemiology Drug Use Review Date: April 5, 2012 To: Edward Cox, M.D. Director Office of Antimicrobial Products Through: Gerald Dal Pan, M.D., MHS Director Office of Surveillance and Epidemiology Laura Governale, Pharm.D., MBA Deputy Director for Drug Use Division of Epidemiology II Office of Surveillance and Epidemiology Hina Mehta, Pharm.D. Drug Use Data Analysis Team Leader Division of Epidemiology II Office of Surveillance and Epidemiology From: Tracy Pham, Pharm.D. Drug Use Data Analyst Division of Epidemiology II Office of Surveillance and Epidemiology Drug Name(s): Systemic Antibacterial Drug Products Application Type/Number: Multiple Applicant/sponsor: Multiple OSE RCM #: 2012-544 **This document contains proprietary drug use data obtained by FDA under contract. The drug use data/information in this document has been cleared for public release.** 1 EXECUTIVE SUMMARY The Division of Epidemiology II is providing an update of the drug utilization data in terms of number of kilograms or international units of selected systemic antibacterial drug products sold from manufacturers to various retail and non-retail channels of distribution for years 2010-2011 as a surrogate for nationwide antibacterial drug use in humans. Propriety drug use databases licensed by the FDA were used to conduct this analysis. Data findings are as follows: During years 2010 and 2011, the majority of kilograms of selected systemic antibacterial drug products sold were to outpatient retail pharmacy settings. Approximately 3.28 million kilograms of selected systemic antibacterial drug products were sold during year 2010, and around 3.29 million kilograms were sold during year 2011.
    [Show full text]
  • WO 2010/025328 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 4 March 2010 (04.03.2010) WO 2010/025328 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US2009/055306 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 28 August 2009 (28.08.2009) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (26) Publication Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/092,497 28 August 2008 (28.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): FOR¬ GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, EST LABORATORIES HOLDINGS LIMITED [IE/ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, —]; 18 Parliament Street, Milner House, Hamilton, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, Bermuda HM12 (BM).
    [Show full text]
  • A New Trigger of Morbilliform Eruption in the Setting of Atypical Infectious
    A New Trigger of Morbilliform Eruption in the Setting of Atypical Infectious Mononucleosis Roxanne Rajaii, DO,* Megan Furniss, DO,** John Pui, MD,*** Brett Bender, DO**** *Dermatology Resident, PGY2, Beaumont Hospital - Farmington Hills, Farmington Hills, MI **Dermatology Resident, PGY4, Beaumont Hospital - Farmington Hills, Farmington Hills, MI ***Dermatopathologist, Beaumont Hospital - Farmington Hills, Farmington Hills, MI ****Dermatologist, Beaumont Hospital - Farmington Hills, Farmington Hills, MI Disclosures: None Correspondence: Roxanne Rajaii, DO; [email protected] Abstract Morbilliform eruptions, also commonly referred to as exanthematous or maculopapular drug eruptions, are the most common type of hypersensitivity reaction and can vary in etiology. Antibiotics are a common trigger, most notably amoxicillin or ampicillin in the setting of a concomitant and acute Epstein-Barr virus (EBV) infection. However, other antibiotics have been identified to cause a similar reaction in the setting of EBV. Cephalexin, a commonly used cephalosporin, is the only antibiotic in its class that has been implicated in causing such a phenomenon. We present a unique case of a morbilliform eruption in the setting of EBV secondary to the use of cefepime, further outlining the importance of conservative antibiotic use and awareness of such a reaction in this specific patient population, not only with penicillins but also with a wider spectrum of antibiotics. Introduction acquired pyelonephritis, as she had been admitted Work-up included the following laboratory tests: Epstein-Barr virus (EBV) infects more than a month prior to that for status asthmaticus. complete blood count, complete metabolic panel, 98% of the world’s adult population and is the Four days later, she presented with an urticarial anti-nuclear antibody, creatinine phosphate kinase, most common cause of infectious mononucleosis morbilliform rash.
    [Show full text]
  • EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use
    Ref. Ares(2019)6843167 - 05/11/2019 31 October 2019 EMA/CVMP/158366/2019 Committee for Medicinal Products for Veterinary Use Advice on implementing measures under Article 37(4) of Regulation (EU) 2019/6 on veterinary medicinal products – Criteria for the designation of antimicrobials to be reserved for treatment of certain infections in humans Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. Introduction On 6 February 2019, the European Commission sent a request to the European Medicines Agency (EMA) for a report on the criteria for the designation of antimicrobials to be reserved for the treatment of certain infections in humans in order to preserve the efficacy of those antimicrobials. The Agency was requested to provide a report by 31 October 2019 containing recommendations to the Commission as to which criteria should be used to determine those antimicrobials to be reserved for treatment of certain infections in humans (this is also referred to as ‘criteria for designating antimicrobials for human use’, ‘restricting antimicrobials to human use’, or ‘reserved for human use only’). The Committee for Medicinal Products for Veterinary Use (CVMP) formed an expert group to prepare the scientific report. The group was composed of seven experts selected from the European network of experts, on the basis of recommendations from the national competent authorities, one expert nominated from European Food Safety Authority (EFSA), one expert nominated by European Centre for Disease Prevention and Control (ECDC), one expert with expertise on human infectious diseases, and two Agency staff members with expertise on development of antimicrobial resistance .
    [Show full text]
  • Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update
    Antibiotic Use for Sepsis in Neonates and Children: 2016 Evidence Update Aline Fuchsa, Julia Bielickia,b, Shrey Mathurb, Mike Sharlandb, Johannes N. Van Den Ankera,c a Paediatric Pharmacology and Pharmacometrics, University Children's Hospital Basel, Basel, Switzerland b Paediatric Infectious Disease Research Group, Institute for Infection and Immunity, St George's University of London, London, United Kingdom c Division of Clinical Pharmacology, Children’s National Health System, Washington, DC, USA WHO-Reviews 1 TABLE OF CONTENTS 1. INTRODUCTION ............................................................................................................................... 3 1.1. Aims ......................................................................................................................................... 3 1.2. Background ............................................................................................................................. 3 1.2.1. Definition and diagnosis ................................................................................................. 3 Neonatal Sepsis ............................................................................................................................... 3 Paediatric Sepsis ............................................................................................................................. 4 Community versus hospital acquired sepsis .................................................................................. 5 1.2.2. Microbiology ..................................................................................................................
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • Beta Lactam Antibiotics Penicillins Pharmaceutical
    BETA LACTAM ANTIBIOTICS PENICILLINS PHARMACEUTICAL CHEMISTRY II PHA386 PENICILLINS Penicillin was discovered in 1928 by Scottish scientist Alexander Fleming, who noticed that one of his experimental cultures of staphylococcus was contaminated with mold (fortuitous accident), which caused the bacteria to lyse. Since mold belonged to the family Penicillium (Penicillium notatum), he named the antibacterial substance Penicillin. Penicillin core structure CHEMICAL STRUCTURE PENAM RING PENICILLIN G 6-APA • 6-APA is the chemical compound (+)-6-aminopenicillanic acid. • It is the core of penicillin. PENAM RING 5 1 • 7-oxo-1- thia-4-azabicylo [3,2,0] heptane 6 2 7 3 4 PENICILLANIC ACID • 2,2–dimethyl penam –3– carboxylic acid • 2,2-dimethyl-7-oxo-1- thia-4-azabicylo [3,2,0]heptane -3-carboxylic acid 6-AMINO PENICILLANIC ACID (6-APA) • 6-amino-2,2–dimethyl penam –3– carboxylic acid • 6-amino-2,2-dimethyl-7-oxo-1- thia-4-azabicylo [3,2,0] heptane-3-carboxylic acid PENISILLIN G (BENZYL PENICILLIN) O S CH3 CH2 C NH CH3 N O COO-K+ 6-(2-Phenylacetamino) penicillanic acid potassium salt PENICILLIN G PROCAINE O C 2 H 5 ‐ H N C H 2 C H 2 O C N H 2 C 2 H 5 PENICILLIN G BENZATHINE ‐ ‐ C H 2 C H 2 H N C H 2 C H 2 N H H H PENICILLIN V (PHENOXYMETHYL PENICILLIN) PHENETHICILLIN PROPACILLIN METHICILLIN SODIUM OCH3 S CH3 CONH CH3 N - + OCH3 O COO Na 6-[(2,6-dimethoxybenzoyl)amino] penicillanic acid sodium salt NAFCILLIN SODIUM 6-(2-ethoxy-1-naphtylcarbonylamino) penicillanic acid sodium salt OXACILLIN SODIUM 6-[(5-methyl-3-phenylizoxazole-4-yl)-carbonylamino] sodium
    [Show full text]